流感疫苗安全性大比拼：亚单位疫苗 VS 裂解病毒疫苗

Core Viewpoint - The article discusses the safety and effectiveness of two types of influenza vaccines, "subunit" vaccines and "split virus" vaccines, based on a large clinical trial conducted in India, highlighting their comparable safety profiles for healthy adults and the elderly [2][19]. Group 1: Introduction and Background - Influenza poses a significant public health threat globally, particularly to high-risk groups such as children, the elderly, pregnant women, and those with chronic illnesses, making vaccination the most effective preventive measure [3]. - The market offers trivalent (TIV) and quadrivalent (QIV) vaccines, with QIV being preferred in many countries due to its broader protection against two B virus lineages [3]. - India faces unique challenges in influenza control, with a reported 28,798 cases of H1N1 and 1,218 deaths in 2019, indicating a potentially higher actual infection burden due to underreporting [5]. Group 2: Vaccine Types and Research Methodology - Subunit vaccines retain only immunogenic surface proteins, while split virus vaccines preserve the complete viral structure, leading to differences in protein content [6]. - The study was a randomized, observer-blind, active-controlled Phase III clinical trial conducted in March-April 2018 across 12 centers in India, involving 480 healthy participants aged 18-60 and elderly individuals aged 61 and above [8]. Group 3: Safety Comparison - Both vaccine types exhibited low adverse reaction rates, with 0.8% in the test group and 0.4% in the control group, and no serious adverse events or deaths reported [10]. - Local and systemic reactions were mild, with incidences below 5% in both groups, showing no significant differences [12]. - Local reactions included pain at the injection site (2.5% for subunit and 3.0% for split virus), while systemic reactions were most commonly fever (2.9% for subunit and 1.6% for split virus) [14]. Group 4: Discussion and Future Directions - The study confirms that both vaccine types are safe for healthy adults and the elderly in India, providing critical data for influenza prevention strategies [16]. - Limitations include the exclusion of immunocompromised or high-risk populations, a small sample size, and the absence of data on children and adolescents [17]. - Future research should focus on high-risk groups and consider regional differences in influenza prevalence to optimize vaccination strategies [18].